TRON Group Inc. (OTCPK:TGRP) entered into a definitive agreement to acquire Nanopharmaceutics, Inc. on August 11, 2022. Under the terms of the agreement, in an all-stock transaction, Nano and TRON will merge. TRON will issue five shares of recently authorized and designated Class A Preferred stock to Nano shareholders in exchange for all the issued and outstanding shares of Nano. Following consummation of the merger, TRON will change its name to Nanopharmaceutics, Inc. and will continue to trade on the OTC Pink market. James D. Talton, President and Chief Executive Officer and controlling shareholder of both TRON and Nanopharmaceutics, has been appointed Chief Executive Officer, President, Secretary/Treasurer and Director of TRON, effective August 8, 2022. The Board of Directors will initially be comprised of three members including current TRON directors, Quoc Tuan (Jacob) Nguyen and Stephen Michael Griffith., and Dr. Talton, who will also continue to serve as an officer and director of Nano. The combined company's headquarters will be located in Alachua, Florida. The merger was unanimously approved by both Boards of Directors of TRON and Nano.